DB
PRAX icon

Dmitry Balyasny’s Praxis Precision Medicines PRAX Stock Holding History

Dmitry Balyasny’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3,333
Closed -$123K – 3176
2022
Q2 		$123K Buy
+3,333
New +$356K ﹤0.01% 2259

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Dmitry Balyasny's PRAX Position: Q2 2026 in Review

Dmitry Balyasny opened a new position in Praxis Precision Medicines (PRAX) in Q2 2026: 1,880 shares worth $629K. The stake represents ﹤0.01% of the portfolio and ranks #2426 among its holdings. This is a return to the name: Dmitry Balyasny previously reported a position in PRAX as recently as Q2 2025.

Dmitry Balyasny first reported a position in PRAX in Q3 2022 and has held it in 6 quarters since. The position peaked at $15.5M in Q2 2025. 307 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Dmitry Balyasny held 1,880 shares of Praxis Precision Medicines worth $629K as of Q2 2026.
  • Praxis Precision Medicines was a new Dmitry Balyasny position in Q2 2026.
  • Praxis Precision Medicines made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #2426 holding.
  • Dmitry Balyasny first reported a position in Praxis Precision Medicines in Q3 2022 and has held it in 6 quarters since.
  • Dmitry Balyasny's Praxis Precision Medicines position peaked at $15.5M in Q2 2025.
  • 307 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.